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Background: The aim of this study was to assess the reasons for discontinuing or   continuing 
olanzapine in patients with schizophrenia, from the perspectives of the patients and their 
clinicians.
Methods: The Reasons for Antipsychotic Discontinuation/Continuation (RAD) is a pair of 
questionnaires assessing these reasons from the perspectives of patients and their clinicians. 
Outpatients with schizophrenia (n = 199) who were not acutely ill participated in a 22-week 
open-label study of olanzapine from November 2006 to September 2008. Reasons for continu-
ing or discontinuing olanzapine (on a five-point scale), along with the single most important 
reason and the top primary reasons, were identified. Concordance between reasons given by 
patients and clinicians was assessed.
Results: The top primary reasons for continuing olanzapine were patients’ perceptions of 
improvement, improvement of positive symptoms, and improved functioning. The study 
  discontinuation rate was low (30.2%), and only a subset of patients who discontinued reported 
reasons for medication discontinuation. The top primary reasons for discontinuing   olanzapine 
were insufficient improvement or worsening of positive symptoms, adverse events, and insuf-
ficient improvement or worsening of negative symptoms. Ratings given by patients and   clinicians 
were highly concordant.
Conclusion: The main reason for continuing or discontinuing olanzapine appears to be 
  medication efficacy, especially for positive symptoms. Reasons for medication discontinua-
tion differ somewhat from reasons for continuation, with a high level of concordance between 
patient and clinician responses.
Keywords: antipsychotic agents, schizophrenia, olanzapine, questionnaires
Introduction
Treatment discontinuation for any cause is considered a proxy measure of effective-
ness of a medication (or lack thereof), reflecting its efficacy, safety, and tolerability.1 
Prior studies1 have assessed reasons for discontinuation of medication using only a few 
categories (eg, patient decision, lack of efficacy, or medication intolerability). These 
responses do not identify the specific reasons for medication discontinuation from a 
patient perspective, clinician perspective, or both, and require respondents to choose 
only one reason when more than one may apply. Furthermore, reasons for continuing 
a medication have seldom been collected. In response to sparse data regarding patient 
discontinuation or continuation of medications, two measures were developed to assess 
the specific Reasons for Antipsychotic Discontinuation/Continuation (RAD), one from 
the clinician perspective2 and one from the patient perspective.3Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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In a previous 12-week study4 of markedly ill   schizophrenia 
patients experiencing acute psychotic exacerbations, 
improvement of positive symptoms was found to be the 
single most important reason for continuation of medication, 
and lack of improvement or worsening of positive symptoms 
was the most important reason for discontinuation of medi-
cation, from the perspectives of both patient and clinician. 
However, it is unclear if these findings were an artifact of 
patient selection criteria, because improvements in positive 
symptoms are expected to be highly valued by markedly ill 
patients with acute psychotic exacerbations and their   treating 
physicians.
The present study aimed to assess whether the prior 
findings could be replicated when using data on reasons for 
continuing or discontinuing olanzapine among moderately 
ill outpatients with schizophrenia, who were not required to 
be acutely ill or to have prominent positive symptoms to be 
enrolled in the study. The primary objective was to assess 
prospectively the specific reasons for continuing or discon-
tinuing olanzapine therapy in outpatients with schizophrenia, 
from both patient and clinician perspectives.
Materials and methods
Data on reasons for continuing or discontinuing olanzapine 
therapy were collected during a multicenter,   randomized, 
open-label, 22-week international trial that enrolled 
199 outpatients with schizophrenia from November 2006 
to September 2008. The study was designed to determine if 
weight gain during olanzapine treatment can be prevented or 
mitigated using an algorithm including adjunctive medication 
with amantadine, metformin, or zonisamide. Patients were 
randomized 3:1 to receive either olanzapine in combination 
with an adjunctive medication algorithm plus behavioral 
instruction (n = 149) or olanzapine alone plus behavioral 
instruction (n = 50). Patients randomized to treatment with 
the adjunctive medication were randomized again, 1:1, to 
a pharmacological algorithm beginning with amantadine 
(n = 76) or an algorithm beginning with metformin (n = 73). 
Details about the parent study are available elsewhere.5
Written informed consent was obtained from all patients 
after they received a complete description of the study. All 
procedures were approved by institutional review boards for 
all study sites and were conducted in compliance with the 
Declaration of Helsinki.
Patients included men and women aged 18–65 years 
with schizophrenia or schizoaffective disorder (295.XX 
from DSM-IV-TR [Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition, Text Revision]) having 
a body mass index of 20–35 kg/m2, with a maximum of 
25% of patients at ,23 kg/m2 or .30 kg/m2. Investigators 
determined that each patient required a change in current 
antipsychotic treatment and that olanzapine was a reasonable 
choice. Patients requiring treatment with mood stabilizers 
or antidepressants had to be stabilized on these medications 
with no changes in therapy in the 30 days prior to the screen-
ing visit and no changes during the study. Patients were 
excluded if, in the opinion of the investigator, they were 
resistant to treatment with olanzapine; had a substance 
dependence diagnosis (other than nicotine or caffeine) within 
30 days prior to the screening visit; had a plasma prolactin 
  concentration .200 ng/mL at the screening visit; had a 
history of eating disorders (307.XX); or was on current treat-
ment with amantadine, metformin, or zonisamide. Patients 
diagnosed with diabetes or receiving treatment or nutrition 
therapy for diabetes were also excluded.
Measures
rAD
Two measures previously developed to assess RAD were 
recently validated using clinical trial data.6 One is a semi-
structured interview conducted by trained interviewers to 
assess patient reasons for discontinuing or continuing their 
antipsychotic medications (RAD-I).3 Data were collected 
by having interviewers complete the measure and choose 
the appropriate options based upon information they col-
lected during the patient interviews. The second measure is 
a questionnaire assessing patient reasons for discontinuing 
or continuing their medications from the clinician perspec-
tive (RAD-Q).2
The RAD-I and RAD-Q include 25 items assessing 
reasons for discontinuation of medication and 21 (RAD-I) 
or 18 (RAD-Q) items assessing reasons for continuation of 
  medication. The items were selected based on a comprehen-
sive literature review, a patient interview pilot study, and input 
from an expert working group. Patients with schizophrenia 
or schizoaffective disorder and their clinicians completed the 
draft measures and structured cognitive debriefing interviews 
assessing the comprehensibility, clarity, and comprehensive-
ness of the measure. The draft measures were further revised 
following cognitive debriefing interviews with clinicians, 
patients, and interviewers. A detailed description of the devel-
opment of the RAD measures can be found elsewhere.7
In the present study, these measures were assessed at 
baseline to identify reasons for discontinuing medication 
used prior to the study start, at endpoint (22 weeks) to 
assess the reasons for continuing olanzapine therapy, and at Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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discontinuation (if the patient discontinued olanzapine prior 
to study completion) to identify the reasons for discontinu-
ing treatment with olanzapine. Selected items of the RAD 
instruments are presented in Table 1. Each reason was rated 
as a primary reason, a very important reason, a somewhat 
important reason, a minor reason, or not a reason. After the 
reasons were identified and rated, the single most important 
reason was also identified. Patients were interviewed to col-
lect their responses on the RAD, and interpretations were 
derived from the RAD data and not from statements made 
during the interview.
statistical methodology
Statistical analyses were completed for the reasons patients 
discontinued the medication used prior to the study, the 
reasons for discontinuing olanzapine (if discontinued), and 
the reasons for continuing olanzapine (if the study was 
completed). Descriptive statistics were used to assess the fre-
quency with which patients (RAD-I) and clinicians (RAD-Q) 
identified each of the reasons as the single most important 
reason and/or a primary reason(s). Analysis combined “symp-
toms not sufficiently improved” and “symptoms made worse” 
into a single item, ie, “symptoms not sufficiently improved or 
made worse.” Paired t-tests were used to compare the mean 
number of any reasons reported by patients versus those 
reported by clinicians. Spearman correlation coefficients were 
calculated to assess concordance between the group rankings 
of all the patient reasons and the group rankings of all the 
clinician reasons (for the single most important reason and 
again for the primary reason). Fisher’s Exact test was used to 
assess the association between discontinuing the prior drug 
due to positive symptoms as a primary reason and continuing 
olanzapine due to positive symptoms as a primary reason.
Results
The RAD measures were administered to 199 outpatients at 
study entry, and data were available for 191 patients. Their 
baseline characteristics are presented in Table 2, showing 
that, on average, patients were in their late 30s, mostly 
male, about 44% Caucasian, and about 26% Hispanic. They 
had a mean Clinical Global Impressions-Severity (CGI-S) 
score of 4.0.
reasons for continuing olanzapine
Study completion rate was relatively high (70%). Of the 139 
patients who completed the study, about half of the patients 
(n = 69, 49.6%) and their clinicians (n = 58, 41.7%) reported 
reasons for continuing olanzapine. Of 139 patients who fin-
ished the study, 70 (50.4%) had data from the Reasons for 
Medication Continuation measure. Among patients continu-
ing on olanzapine, those who had data from this measure did 
not differ significantly on baseline characteristics from those 
who did not have data from this measure. The mean num-
bers of reasons for continuing olanzapine given by patients 
and clinicians were 8.5 (standard deviation [SD] = 4.0) and 
7.3 (SD = 2.6), respectively (P = 0.009). From the patient 
perspective, the reasons given as the single most important 
Table  1  select  items  from  the  reasons  for  antipsychotic 
discontinuation/continuation
Reasons for discontinuation
•   This medication did not sufficiently improve positive symptoms  
(eg, hallucinations, delusions)
•   The patient has not formed a therapeutic alliance or connection with 
members of the treatment team
•   This medication did not sufficiently improve negative symptoms  
(eg, flat affect, lack of motivation)
• Adverse effects (specified)
•   The medication has serious safety issues that are dangerous and 
potentially life-threatening for this patient (eg, seizures, heart 
arrhythmia)
•   Potential interactions with another drug prescribed for this patient
•   This medication did not sufficiently improve mood (eg, depression)
•   This medication did not sufficiently improve cognition (eg, planning, 
attention)
•   This medication did not sufficiently improve functional status  
(eg, self-care activities of daily living or work)
• Patient believes medication is no longer necessary
• Cost of the medication
• nonadherence with medication
• Patient wishes to try another medication
• Other, specify
Reasons for continuation
•   Benefits for negative symptoms (eg, flat affect, lack of motivation)
•   Benefits for positive symptoms (eg, hallucinations, delusions)
• Benefits for mood (eg, depression)
•   Medication has no serious safety issues that are dangerous and 
potentially life-threatening for this patient (eg, seizures, heart 
arrhythmia)
•   The patient has formed a therapeutic alliance or connection with 
members of the treatment team
• Financial cost of medication
• The patient’s insurance adequately covers this medication
• Benefits for cognition (eg, planning, attention, memory)
•   Benefits for functional status (eg, self-care activities of daily living, or 
work)
•   social support (eg, friends or family support the patient in taking this 
medication)
•   Patient perceptions of improvement (eg, the patient believes he/she is 
now “better” and wants to continue taking the medication)
•   The patient has already tried other antipsychotics that have not been 
as effective and/or tolerable
• Other, specifyPatient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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reason for continuing olanzapine were “benefits functioning” 
(25.0%), “patient’s perceptions of improvement” (23.3%), 
and “benefits positive symptoms” (13.3%). From the clini-
cian perspective, the most frequently identified reasons were 
“benefits positive symptoms” (24.5%), “patient’s percep-
tions of improvement” (22.6%), and “benefits functioning” 
(20.8%). For patients and clinicians, the top primary reasons 
for continuing olanzapine were “patient’s perceptions of 
improvement” (29.0% and 25.9%), “benefits positive symp-
toms” (24.6% and 24.1%), and “benefits functioning” (24.6% 
and 24.1%, respectively, Figure 1).
reasons for discontinuing olanzapine
A total of 60 patients (30.2%) discontinued the study. Fewer 
than half of these patients (n = 24, 40%) and their clinicians 
(n = 23, 38.3%) reported reasons for discontinuing olanzapine. 
Among patients discontinuing olanzapine, those who did not 
respond to the Reasons for Medication Discontinuation mea-
sure were significantly more likely to be African-American 
or Hispanic, and had more depressive symptoms, greater 
illness severity, and poorer quality of life than patients who 
discontinued the study and responded to this measure.
The mean number of reasons for discontinuing olan-
zapine from the patient perspective was 2.3 (SD = 2.9) and 
3.7 (SD = 5.4) from the clinician perspective. These means 
were not significantly different (P = 0.223). From the patient 
perspective, the reasons given as the single most important 
reason for discontinuing olanzapine were “adverse events” 
(28.6%) and “mood not sufficiently improved or made worse” 
(19.0%). From the clinician perspective, the reasons given 
were “adverse events” (30.0%), “nonadherence with medi-
cation” (25.0%), and “positive symptoms not sufficiently 
improved or made worse” (20.0%).
The top primary reasons for discontinuing olanzapine 
from the patient perspective were “positive symptoms not 
sufficiently improved or made worse” (25.0%), “adverse 
events” (16.7%), and “negative symptoms not sufficiently 
improved or made worse” (12.5%, Figure 2). The adverse 
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Figure 1 Primary reasons for continuing on olanzapine (n = 69 patients; n = 58 clinicians).
Table  2  Baseline  characteristics  of  191  study  patients  with 
reasons for Antipsychotic Discontinuation/Continuation (rAD-i 
[patient]) or rAD-Q [clinician]) data
Age (years, mean, sD) 38.6 (±12.0)
gender
  Female 76 (39.8%)
  Male 115 (60.2%)
ethnicity/race
  Caucasian (n, %) 84 (44.0%)
  African descent (n, %) 14 (7.3%)
  east Asian (n, %) 38 (19.9%)
  hispanic (n, %) 50 (26.2%)
  native American (n, %) 1 (0.5%)
  West Asian 4 (2.1%)
MADrs total (mean, sD) 14.3 (9.8)
BPrs total score (mean, sD) 47.0 (14.2)
BPrs positive score (mean, sD) 12.3 (5.5)
Cgi-s (mean, sD) 4.0 (1.1)
eQ-5D (mean, sD)
  Us Population-Based index score 0.7 (0.2)
  Visual Analog scale health state score 62.1 (24.3)
Weight (kg, mean, sD) 77.6 (16.7)
Body mass index (mean, sD) 27.1 (4.7)
Abbreviations:  BPrs,  Brief  Psychiatric  rating  scale;  Cgi-s,  Clinical  global 
impression-severity;  eQ-5D,  european  Quality  of  Life-5  Dimensions;  MADrs, 
Montgomery-Åsberg Depression rating scale; sD, standard deviation.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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events were vomiting, hyperglycemia, insomnia, nausea, and 
oversleep, each reported by one patient. The top primary rea-
sons from the clinician perspective were “positive symptoms 
not sufficiently improved or made worse” (26.1%), “adverse 
events” (26.1%), and “nonadherence with medication” 
(13.0%). The adverse events included tingling sensation in 
legs, dizziness, hyperglycemia, somnolence, and insomnia, 
each recorded by one clinician.
reasons for discontinuing drug used 
prior to study start
Prior to the study start, 24.9% of patients were treated with 
oral risperidone, 24.3% with typical antipsychotic drugs, 
30.5% with “other drugs” (primarily quetiapine and arip-
iprazole), and there was no information for 20.3%. Of the 
199 patients, 177 (88.9%) had RAD data for discontinuing 
the drug used prior to study start. The mean numbers of 
reasons given by patients and clinicians were 4.1 (SD = 3.2) 
and 4.6 (SD = 3.1), respectively (P = 0.008). From the patient 
perspective, the reasons given as the single most important 
reason for discontinuing the drug used prior to study start 
were “positive symptoms not sufficiently improved or made 
worse” (26.2%), “patient wishes to try a new antipsychotic” 
(21.6%), and “adverse events” (19.0%). The most common 
adverse events were akathisia and tremors. From the clini-
cian perspective, the reasons given were “positive symptoms 
not sufficiently improved or made worse” (32.4%), “adverse 
events” (20.3%), and “patient wishes to try a new antipsy-
chotic” (12.8%). The adverse events reported most frequently 
were extrapyramidal symptoms and weight gain.
For patients, the top primary reasons for   discontinuing 
prior drugs were “positive symptoms not sufficiently 
improved or made worse” (15.3%), “patient wishes to try a 
new   antipsychotic” (11.8%), and “adverse events”/“functional 
status not sufficiently improved or made worse” (both 
10.6%,   Figure 3). For clinicians, the reasons were “  positive 
  symptoms not sufficiently improved or made worse” 
(20.2%), “negative symptoms not sufficiently improved or 
made worse” (11.6%), and “functional status not sufficiently 
improved or made worse” (11.0%).
Concordance between patients’  
and clinicians’ ratings
For the single most important reason, there were statistically 
significant correlations between patient and clinician reasons 
for continuing olanzapine (rs = 0.96; P , 0.0001), discontinu-
ing olanzapine (rs = 0.58; P = 0.003), and discontinuing the 
medication used prior to study start (rs = 0.91; P , 0.0001). 
Statistically significant correlations were also found for 
the primary reasons for continuing olanzapine (rs = 0.96; 
P , 0.0001), discontinuing olanzapine (rs = 0.64; P = 0.001), 
and discontinuing the medication used prior to study start 
(rs = 0.92; P , 0.0001).
Patient continuation on olanzapine  
and discontinuation of prior drugs
Of the 70 patients who had either RAD-I or RAD-Q 
  continuation measures, 10 discontinued prior drugs due to 
“positive symptoms not sufficiently improved or made worse” 
as a primary reason and 60% of those patients (six of ten) 
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continued   olanzapine due to “benefits for positive symptoms” 
as a primary reason. For the other 60 patients, only 23.3% 
(14 of 60) continued olanzapine due to “benefits for positive 
symptoms” as a primary reason. There was a significant asso-
ciation between discontinuing the prior drug due to “positive 
symptoms not sufficiently improved or made worse” as a 
primary reason and continuing olanzapine due to “benefits 
for positive symptoms” as a primary reason (P = 0.027). 
The patients who discontinued the prior drug due to “posi-
tive symptoms not sufficiently improved or made worse” 
as a primary reason had about five times higher odds (odds 
ratio = 4.93, 95% confidence interval 1.22–19.98) of continu-
ing with olanzapine due to “benefits for positive symptoms” 
as a primary reason than other patients.
Discussion
This study assessed the specific reasons patients and their 
clinicians reported for continuing or discontinuing olanzap-
ine in the treatment of schizophrenia over a 22-week period. 
Using the recently validated RAD-I and RAD-Q measures,6 
this study found that continuation of olanzapine appears to be 
driven primarily by efficacy, including general improvement 
perceived by patients, and improvement in positive symptoms 
and level of functioning. Discontinuing olanzapine in this 
study (30%) appeared to be primarily driven by lack of medi-
cation efficacy, especially on positive symptoms, followed 
by adverse events (eg, vomiting, nausea, tingling sensation 
in legs, dizziness, hyperglycemia, insomnia, oversleep, and 
somnolence) and insufficient improvement or worsening of 
negative symptoms according to the primary reasons given 
on the RAD measures. These results are consistent with a 
previous 12-week study of markedly ill schizophrenia patients 
experiencing acute psychotic exacerbations.4 That study also 
showed that patients and clinicians identified more reasons 
for the continuation of olanzapine than for its discontinuation 
(more than twice as many reasons), and there was a high level 
of concordance between patient and clinician perspectives on 
the reasons for medication continuation or discontinuation.
Participants in the previous study4 were acutely ill patients 
with schizophrenia who experienced a recent exacerbation 
of positive symptoms. These patients had a mean total Brief 
Psychiatric Rating Scale8 score of 54.4 and a CGI-S of 4.6. 
In contrast, the current study included patients who were 
less severely ill, all treated in outpatient settings, with Brief 
Psychiatric Rating Scale and CGI-S mean scores of 46.9 and 
4.0, respectively. Despite the differences in the illness severity 
profile of the patient populations, both studies demonstrated 
that continuation and discontinuation appear to be driven 
by medication efficacy for improving positive symptoms, 
whereas the reasons for medication discontinuation appear to 
be driven by both efficacy and medication-emergent adverse 
events. The replication of the previous findings in a less ill 
patient population suggests that the core reasons for continu-
ing or discontinuing atypical antipsychotic medications can 
generalize across patient populations and are not unique to 
acutely ill psychotic patients with schizophrenia.
Current findings are also consistent with prior research 
demonstrating that continuing or discontinuing antipsychotic 
medications is driven primarily by medication efficacy.1,9–14 
Although clinicians have long believed that medication 
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safety and tolerability are the main drivers of   medication 
  discontinuation, the Clinical Antipsychotic Trials of 
Intervention Effectiveness study and other studies9 have 
shown the greater importance of efficacy. Recent studies 
have demonstrated that patient perceptions of medication 
benefits and treatment response (especially on positive 
symptoms) are robust predictors of treatment continuation/
discontinuation.4,10,15–17
A recent study by Campbell et al18 suggests that focus on 
a single symptom dimension or treatment-emergent adverse 
event may not fully capture the combination of variables 
that clinicians consider when prescribing antipsychotics. 
These investigators used a recently developed questionnaire 
(Antipsychotic Treatment Choice Questionnaire) to quantify 
risks and benefits that psychiatrists consider when choosing 
an antipsychotic medication. The prescribing decisions of 
four psychiatrists who initiated antipsychotic medication with 
80 patients were examined. Results showed that the predicted 
certainty of symptom control and metabolic risk correlated 
significantly and independently with treatment decisions. 
A patient’s history of treatment response and severity of 
positive symptoms were frequently cited as most important 
by psychiatrists in making a treatment decision.
The findings of the present study need to be evaluated 
in the context of the study limitations. The most important 
limitation is that RAD results were not available for all 
patients who continued or discontinued the study medication. 
Despite a high study completion rate of 70%, only 50% of the 
patients who completed the study responded to the Reasons 
for Medication Continuation measure. Furthermore, only 
40% of patients who discontinued the study completed the 
Reasons for Medication Discontinuation measure. There was 
no way to fill in missing data in the RAD, and data were not 
collected that would discern if patients refused to respond to 
the RAD or were lost to follow-up. This made it unfeasible 
to assess differences in reasons for discontinuation across 
time in this study. Because these patients were in an open-
label olanzapine study, they were choosing to participate 
and wanted to receive olanzapine treatment. This may have 
provided more reasons to continue with the study and may 
have added to the high completion rate. It should be pointed 
out that reasons for continuation or discontinuation may dif-
fer in those who are nonresponders to the measures given. 
In addition, excluding patients with diabetes also limits the 
generalizability of the results. Therefore, it is unclear whether 
reasons cited for medication continuation or discontinua-
tion in this clinical trial differ from those reported in usual 
clinical practice.
In summary, the results from this study in an outpatient 
population with schizophrenia demonstrate that continuing or 
discontinuing olanzapine is primarily driven by medication 
efficacy. These results, in a less severely ill population, are 
consistent with results observed earlier in acutely ill psychotic 
patients with schizophrenia.
Conclusion
The main reason for continuing or discontinuing olan-
zapine appears to be medication efficacy, especially for 
positive symptoms. Reasons for medication discontinua-
tion differ somewhat from reasons for continuation, with 
a high level of concordance between patient and clinician 
responses.
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